# Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)

> **NCT00413387** · PHASE3 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 219 (actual)

## Conditions studied

- Bronchial Asthma

## Interventions

- **DRUG:** beclomethasone dipropionate plus formoterol fumarate combination
- **DRUG:** budesonide plus formoterol combination

## Key facts

- **NCT ID:** NCT00413387
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2005-08
- **Final completion:** 2005-10
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2020-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00413387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00413387, "Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00413387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*